---945x532.jpg?sfvrsn=73000500_2)
Precision Radiotherapy and the PACE-B Framework
The landscape of prostate cancer treatment in England is undergoing a significant shift as NHS England integrates stereotactic body radiotherapy (SBRT)-also referred to as stereotactic ablative radiotherapy (SABR)-into standard clinical practice. This transition, informed by the PACE-B trial led by The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, allows for a drastic reduction in treatment duration for eligible patients and marks one of the most substantial changes to prostate radiotherapy pathways since the roll-out of intensity-modulated radiotherapy over a decade ago.
While standard external radiotherapy typically requires 20 sessions delivered over four weeks, SBRT utilizes highly concentrated, precise energy beams to deliver a higher dose of radiation to the tumor. This precision minimizes the impact on surrounding healthy tissue, making it an effective alternative for localized, low-to-medium risk cancers. All 48 radiotherapy centers across England are slated to implement this five-session protocol within a three-month window, under the commissioning and service-specification arrangements set out by NHS England as the national commissioner of specialised radiotherapy services.
Clinical Eligibility and Patient Selection
The application of SBRT is not universal; it is strictly reserved for patients who meet specific clinical criteria to ensure safety and efficacy. The protocol is designated for:
- Men with early-stage prostate cancer.
- Cancers that remain localized and have not grown outside the prostate gland.
- Cases classified as low or medium risk in terms of growth or metastasis.
For patients whose cancer has already spread or is more aggressive, standard radiotherapy remains the preferred clinical route, as its wider beams are better suited to targeting cancer cells that may have migrated beyond the primary tumor site. Clinicians will continue to make case-by-case decisions within multidisciplinary teams, balancing SBRT against surgery, systemic therapies and conventional radiotherapy, and aligning choices with national guidelines issued by bodies such as the National Institute for Health and Care Excellence.
Comparative Outcomes and Safety Data
The phase III international randomised PACE-B trial provided the evidence base for this policy shift, comparing the five-session SBRT approach against the conventional intensity-modulated radiotherapy (IMRT). The findings indicate that the condensed schedule does not compromise the long-term control of the disease and offers a safety profile that is broadly comparable to the existing standard of care.
| Metric (5-Year Follow-up) | SBRT (5 Sessions) | Conventional IMRT (20 Sessions) |
|---|---|---|
| Cancer Control Rate | 96% | 95% |
| Genital/Urinary Side Effects (Grade 2+) | 5.5% | 3.2% |
| Gastrointestinal Side Effects (Grade 2+) | <1% (1 patient) | <1% (1 patient) |
Professor Emma Hall, Director of the Clinical Trials and Statistics Unit at The Institute of Cancer Research, London, which managed the PACE-B trial, said: “I am delighted to see that SBRT, offering patients treatment in just five doses rather than 20, is now being recommended by the NHS. Treating patients in a fraction of the time is a game-changer – they can spend less time in hospital and travelling to appointments, whilst still receiving highly effective treatment.” Her comments underscore a key point for policymakers: treatment innovation is delivering efficiency gains without sacrificing clinical outcomes.
Systemic Impact on Healthcare Capacity
Beyond individual patient outcomes, the adoption of SBRT addresses critical pressures within the UK healthcare infrastructure. By reducing the number of required hospital visits per patient by 75%, the NHS can reallocate significant resources to manage oncology waiting lists and increase overall patient throughput at a time when cancer services are under intense performance scrutiny.
NHS England’s operational modeling highlights the following systemic implications:
- Annual Adoption: Approximately 3,500 eligible men are expected to opt for SBRT over standard radiotherapy each year.
- Capacity Gain: If 20% of eligible patients transition to this model, the health service could recover an estimated 50,000 appointment slots annually, freeing machine and staff time for more complex or advanced cases.
- Patient Burden: A reduction from 20 to 5 visits significantly lowers the socioeconomic burden on patients, including reduced travel costs, fewer overnight stays and less time away from employment or caring responsibilities.
Health leaders frame the move as a case study in how evidence from large-scale clinical trials can be translated rapidly into service design and resource planning. The SBRT model aligns with wider NHS strategies to shorten treatment pathways, cut waiting times and standardise access to advanced technologies across regions, rather than confining them to a small number of teaching hospitals.
Professor Nicholas van As, Consultant Clinical Oncologist at The Royal Marsden NHS Foundation Trust, Professor in Precision Prostate Radiotherapy at The Institute of Cancer Research, London, and Chief Investigator of the PACE-B trial, said: “We are delighted that eligible prostate cancer patients across England will now be able to benefit from this treatment following NHS England’s announcement. The news demonstrates the value of clinical research in improving cancer care. At The Royal Marsden and the ICR, we are focused on developing smarter, better and kinder treatments for patients across the UK and around the world. The PACE-B trial was designed to answer an important question: can we safely deliver prostate radiotherapy in far fewer treatment sessions without compromising outcomes? The results showed that we can. Delivering treatment in just five sessions was as safe and effective as conventional radiotherapy, while significantly reducing the burden of treatment for patients. The findings helped establish the evidence base for wider adoption of the treatment and have informed clinical practice internationally.”
Professor Peter Johnson, NHS National Clinical Director for Cancer, said: “This technology lets us focus a powerful and precise beam of radiotherapy directly onto the cancer, limiting the damage to healthy cells. And the fact it can be delivered in 15 fewer doses will help men get back to living their lives far more quickly.” For a system under pressure to meet constitutional cancer targets, that combination of precision medicine and operational efficiency is likely to shape future decisions on how new radiotherapy technologies are evaluated, funded and rolled out across the public sector.
